Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Ketamine for methamphetamine use in young people

To see complete record on, please visit this link

Id: ACTRN12621000528853

Organisation Name: Orygen National

Overal Status: Not yet recruiting

Start Date: 17/05/2021

Brief Summary: This is an open-label Phase II pilot study to investigate the safety and tolerability of two doses of ketamine in young people with stimulant use disorder, methamphetamine-type seeking treatment to reduce their methamphetamine use. The study treatments will be provided in addition to treatment-as-usual received by participants during their regular clinical care. All participants will be engaged with a GP or psychiatrist, either through headspace, Orygen, or in the community, and they will be offered referral into outpatient alcohol and other drug treatment at headspace or in the community. They will receive psychiatric and medical review by the study doctor during screening and at weeks 1 and 2. Participants will complete comprehensive screening and baseline testing. They will then undergo two ketamine administration sessions (subcutaneous; initial dose 0.75 mg/kg) separated by at least 7 days. Assessments will occur at baseline and weeks 2, 3, 4, and 6.

  • Australia

Total execution time in seconds: 0.15543389320374